COVID virus attacking nerves

Alzheimer’s Disease and COVID-19

Angie Szumlinski Studies

Neurodegenerative disorders that cause dementia increase the risk of contracting severe COVID-19 and dying from the disease. For people with Alzheimer’s the risk is three times greater. It can be six times greater if they are over 80 years old according to a study conducted in Brazil by researchers at the University of Sao Paulo (USP) and Butantan Institute in …

Anticholinergic Medications and Dementia

Angie Szumlinski Health, Studies

An estimated 47 million people worldwide were living with dementia in 2015, while in the United States, around 5.7 million people have Alzheimer’s dementia. Modifiable risk factors, including hypertension, hearing loss, depression, diabetes, and smoking, account for around 35% of dementia cases. Anticholinergic drugs are another potentially modifiable risk factor. This broad group of drugs acts by blocking the neurotransmitter …

Predict the Future

Angie Szumlinski Health, Studies

A team of researchers at Lund University in Sweden have identified that a simple blood test, couple with brief memory tests, showed who will develop Alzheimer’s disease in the future (within 2-6 years) with a high degree of accuracy (90%). “We show for the first time that a time- and cost-effective diagnostic algorithm clearly outperforms the clinical work-up typically done …

FDA Grants Accelerated Approval for Alzheimer’s Drug

Angie Szumlinski Announcements, News

On June 7, 2021 the FDA approved a new treatment for Alzheimer’s – Aduhelm (aducanumab). The approval was granted through the “accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments”. The director of the FDA’s Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., …

Effect of Sodium Benzoate on Cognitive Function

Angie Szumlinski Health, Studies

Age and female gender are 2 major risk factors for Alzheimer’s disease (AD); two-thirds of older adults with AD are women. Even regarding the difference in longevity, studies suggest that women are still at a higher risk. Among various aging and dementia theories, altered N-MethylD-aspartate receptor (NMDAR)-related neurotransmission is involved in dementia manifestations, including cognitive and behavioral domains. NMDAR overactivation …

Stem Cell – Dementia Treatment

Angie Szumlinski News

Dementia can arise from multiple conditions, and it is characterized by an array of symptoms including problems with memory, attention, communication, and physical coordination. The two most common causes of dementia are Alzheimer’s disease and white matter strokes, which are small strokes that accumulate in the connecting areas of the brain. “It’s a vicious cycle: the two leading causes of …

Aducanumab and Alzheimer’s Disease

Angie Szumlinski News

On November 6, 2020, the US Food and Drug Administration (FDA) advisory committee reviewed issues related to the efficacy and safety of aducanumab, a human IgG1 anti-Aβ monoclonal antibody specific for β-amyloid oligomers and fibrils implicated in the pathogenesis of Alzheimer’s disease. Given the importance of drug innovation for this common and often devastating disease, the abandonment of prior monoclonal …

Comprehensive Care for Alzheimer’s Act

Angie Szumlinski Featured

More than 6 million Americans are living with Alzheimer’s disease or other forms of dementia and the “Comprehensive Care for Alzheimer’s Act” would help the 95% of individuals with dementia that have one or more other chronic conditions, such as hypertension, heart disease and diabetes. The bipartisan bill is expected to reduce medical complications for these patients by creating a …

Loneliness and Alzheimer’s Disease

Angie Szumlinski News

Loneliness has been linked to Alzheimer’s pathology and cognitive function among older adults, but little research has looked at loneliness as a dementia risk factor for younger people. In a study conducted at the Boston School of Medicine, being persistently lonely during midlife (ages 45-64) appears to make people more likely to develop dementia and Alzheimer’s Disease (AD) later in …

Artificial Intelligence – Alzheimer’s

Angie Szumlinski Studies

New treatments for Alzheimer’s disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options. A team at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) has developed an artificial intelligence-based method to screen currently available medications as possible treatments for Alzheimer’s disease. The method could represent a rapid and inexpensive way to …